ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2120

Independent and Combined Impact of Interstitial Lung Disease and Airway Disease on Rheumatoid Arthritis Disease Activity and Infections

Misaki Yoshida1, takeshi Zoshima2, Ichiro Mizushima2 and Mitsuhiro Kawano2, 1Kanazawa University, Fukui, Japan, 2Kanazawa University, Kanazawa, Japan

Meeting: ACR Convergence 2023

Keywords: Disease Activity, Infection, interstitial lung disease, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: How interstitial lung disease (ILD) and airway disease (AD) independently affect the clinical course of rheumatoid arthritis (RA) is unclear since previous studies conflated ILD and AD. We aimed to clarify the effects of ILD, AD, and their combination on RA disease activity and infections.

Methods: RA patients at our facilities during 2011 and 2021 that had chest computed tomography (CT) scans were investigated retrospectively. Baseline was defined as ‘time of first CT scan’, and final observation as ‘last visit’. Two experienced radiologists evaluated CT findings. We excluded patients with incomplete evaluation of ILD/AD in CT scans. The study primary outcome was development of infection requiring hospitalization, while the secondary was RA disease activity at final observation. We compared patients with and without ILD, and with and without AD. To identify factors associated with RA disease activity or infections, multivariate analyses were performed.

Results: We enrolled 569 patients (75.7% female, mean: age 60.9 yrs, observation period 73.9 mo.), including 125 (22.0%) with ILD, 171 (30.1%) AD, and 76 (13.4%) both (Figure 1).

At baseline, ILD+ and AD+ patients were older significantly than ILD– and AD– patients. ILD+ patients received significantly less methotrexate (MTX) than ILD– patients, while treatments for AD+ and AD– patients were comparable. RA disease activity was similar among groups.

At final observation, ILD+ and AD+ patients had significantly higher Disease Activity Score 28 based on C-reactive protein (DAS28-CRP) (mean 2.4 vs. 2.1 and 2.3 vs. 2.1) and Simplified Disease Activity Index (SDAI) (mean 7.6 vs. 5.8 and 7.4 vs. 5.6) than ILD– and AD– patients. ILD+ patients received significantly less MTX but more glucocorticoids than ILD– patients. ILD+AD+ patients had higher RA activity than the other groups.

Analysis of covariance revealed significant association between DAS28-CRP and ILD [F(1,155) = 7.248], but not AD or their interaction. Similar results were found for SDAI. Kaplan-Meier analysis with log-rank tests revealed significantly lower infection-free rate in ILD+ and AD+ than ILD– and AD– patients. In ILD+ patients, the rate decreased prominently after 50 months. The infection-free rate was lower in ILD+AD+ patients than the other groups (Figure 2).

Cox regression analysis revealed significant association between infections and AD (hazard ratio [HR] 1.970, 95% confidence interval [CI] 1.065-3.646), but not ILD or their interaction. Cox regression analysis with time-dependent covariates, categorizing ILD into >50 and ≤50 months, showed significant association between infections and ILD >50 months (HR 3.702, 95% CI 1.637-8.372) and AD (HR 1.744, 95% CI 1.054-2.885), but not ILD ≤50 months.

Conclusion: Disease activity of RA was independently associated with ILD but not AD, suggesting an impact of reduced MTX in ILD. Risks of developing infections included ILD after 50 months and AD, both independently. The ILD+AD+ group showed higher RA activity and a greater susceptibility to infection than the other groups. Careful detection of ILD and AD, along with implementation of safe and effective alternative treatments, is necessary.

Supporting image 1

Schematic representation of the cohort

Supporting image 2

Cumulative rate of total infectious events


Disclosures: M. Yoshida: None; t. Zoshima: None; I. Mizushima: None; M. Kawano: None.

To cite this abstract in AMA style:

Yoshida M, Zoshima t, Mizushima I, Kawano M. Independent and Combined Impact of Interstitial Lung Disease and Airway Disease on Rheumatoid Arthritis Disease Activity and Infections [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/independent-and-combined-impact-of-interstitial-lung-disease-and-airway-disease-on-rheumatoid-arthritis-disease-activity-and-infections/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/independent-and-combined-impact-of-interstitial-lung-disease-and-airway-disease-on-rheumatoid-arthritis-disease-activity-and-infections/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology